The expression of long non-coding RNA HOTAIR in advanced hepatocellular carcinoma and its prognostic correlation with sunitinib therapy

Chenyang Han¹, Yi Yang¹, Li Guo², Qiaobing Guan³, Shuiliang Ruan¹

¹Department of Pharmacy, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China
²Centre Laboratory, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China
³Department of Gastroenterology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China

Submitted: 22 September 2018; Accepted: 3 December 2018
Online publication: 18 March 2021
Arch Med Sci 2022; 18 (1): 71–78
DOI: https://doi.org/10.5114/aoms/100480
Copyright © 2021 Termedia & Banach

Abstract

Introduction: The study was designed to assess the expression of long non-coding RNA HOTAIR (lncRNA HOTAIR) in tissues and peripheral blood of patients with advanced hepatocellular carcinoma (HCC). In addition, we also investigated the prognostic correlation between the expression level of lncRNA HOTAIR in tumour tissues and peripheral blood of patients with advanced HCC and sunitinib monotherapy.

Material and methods: A total of 60 patients with advanced HCC who received sunitinib monotherapy and another 60 healthy individuals who were examined at the physical examination centre during the same period were included in the study. Real-time quantitative PCR (RT-QPCR) was used to determine the relative expression of lncRNA HOTAIR in tumour tissue, adjacent tissue, and peripheral blood of HCC patients as well as peripheral blood of healthy controls. Moreover, the clinicopathological information, overall survival (OS), and progression-free survival (PFS) were collected, followed by correlation analysis with lncRNA HOTAIR expression.

Results: The expression of lncRNA HOTAIR was significantly higher in tumour tissues compared to that in adjacent tissues ($t = 9.03, p < 0.001$). The expression of lncRNA HOTAIR in peripheral blood of HCC patients was higher than that in healthy controls ($t = 8.04, p < 0.001$). There was a correlation between the expression of lncRNA HOTAIR in tumour tissue and peripheral blood in HCC patients ($r = 0.638, p < 0.001$). Patients with low lncRNA HOTAIR expression in tumour tissues harboured significantly longer OS (13.4 vs. 9.5, $p < 0.001$) and PFS (8.4 vs. 6.2, $p < 0.001$) compared to those with high expression. Consistently, patients with low lncRNA HOTAIR expression in peripheral blood had significantly prolonged OS (12.8 vs. 9.1, $p < 0.001$) and PFS (8.9 vs. 6.4, $p < 0.001$) compared to those with high expression. Patients with low expression both in tumour tissue and peripheral blood had prolonged OS (14.3 vs. 8.8, $p < 0.001$) and PFS (10.6 vs. 6.0, $p < 0.001$) compared to the rest of the patients. Cox regression analysis indicated that the expression level of lncRNA HOTAIR in tumour tissue and peripheral blood was an independent predictive factor of OS and PFS in patients with advanced HCC treated by sunitinib.

Conclusions: The expression of lncRNA HOTAIR was up-regulated in tumour tissue and peripheral blood in patients with advanced HCC. In addition, the expression level of lncRNA HOTAIR was one of the indicators predicting the effectiveness of sunitinib therapy.

Key words: lncRNA HOTAIR, sunitinib, hepatocellular carcinoma, real-time quantitative polymerase chain reaction.
Introduction

Primary hepatocellular carcinoma (HCC) is a highly malignant tumour with a high incidence in Asian countries. The pathogenesis of HCC is complicated, and multiple signal transductions are involved in the carcinogenesis and tumour progression [1]. However, HCC is not easily detected in the early stage. A considerable number of patients are already burdened with moderate to advanced stages after diagnosis, and the treatment is extremely difficult. Only 10% to 30% of HCC patients can undergo surgery in the clinic. Transcatheter arterial chemoembolization (TACE), radiofrequency ablation, and other treatments are generally performed in patients who cannot undergo surgery, while chemotherapy and targeted therapy are conducted in the majority of patients [2, 3]. At present, the first choice of chemotherapeutic drugs in HCC treatment is cytotoxic drugs such as gemcitabine and fluorouracil, which are accompanied with heavy side effects and lack of reproducibility [4]. Therefore, targeted therapy is gradually being promoted at present.

Sunitinib is a novel oral small molecule, multi-targeted tyrosine kinase inhibitor. It has been proven that it harbours anti-tumour angiogenesis and anti-tumour activity. Its mechanism is mainly via inhibition of members of the receptor tyrosine kinase (RTK) family, including vascular endothelial growth factor receptor (VEGFR-1/2), platelet-derived growth factor receptor (PDGFR-α/β), foetal liver tyrosine kinase receptor (FLT3), and colony-stimulating factor 1 (CSF-1), etc. [5]. Clinical trials have verified that sunitinib has significant clinical efficacy on gastrointestinal stromal tumours (GIST), metastatic renal cell carcinoma, and HCC, which can prolong overall survival (OS) and progression-free survival (PFS) [6]. However, similar with other targeted drugs, there are obvious individual differences of sunitinib efficacy, with unrevealed reasons for this individualized difference.

Long non-coding RNA (lncRNA) is a member of the non-coding RNA (nc RNA) family. More and more studies have demonstrated that lncRNA is closely associated with tumour progression and chemotherapeutic resistance, etc. [7]. The lncRNA HOTAIR study has shown that it is highly expressed in multiple malignant tumours, which can be used as a prognostic marker of breast cancer and be utilized to predict the prognosis of HCC transplantation. Additionally, other studies have shown that lncRNA HOTAIR is correlated with drug resistance of cisplatin, trastuzumab, etc. Therefore, in this study, from a clinical perspective, we assessed the expression of lncRNA HOTAIR in advanced HCC patients, and we investigated the correlation of lncRNA HOTAIR expression with prognosis following sunitinib therapy, aiming to provide reference and support for personalized medicine in clinical practice.

Material and methods

Origins of cases

Of the 60 patients enrolled in this study, all were diagnosed with advanced HCC (TNM stage III and IV). All patients did not receive any anti-tumour therapy when they were enrolled, including chemotherapy, radiotherapy, or biological therapy. Patients were confirmed by medical history, signs, laboratory examinations, and imaging examinations. These patients were unable to undergo surgical resection or local treatment. The histological tissue obtained by needle biopsy was confirmed as stage III and IV according to the International Union Against Cancer and the American Joint Committee on Cancer TNM staging classification (seventh edition). Among the 60 patients, there were 35 males and 25 females. Before the treatment, the ECOG score of the patients was 0-2, with B or C of Barcelona staging and A or B of Child-Pugh liver function.

Sixty patients were treated with sunitinib monotherapy. All patients were treated with sunitinib malate (Pfizer). In brief, sunitinib was orally administered at a dose of 37.5 mg once daily for 4 consecutive weeks. In the case of drug-related dose-limiting side effects, treatment can be reduced or discontinued, according to the patient’s tolerance, until the emergence of disease progression or death. The dose reduction was performed at a gradient dose of 12.5 mg based on the type and severity of adverse reactions. In the case of 2 consecutive adverse reactions of Grade 3, the drug dose could be reduced by 1 level. In the case of Grade 4 adverse reactions, sunitinib administration was ceased, while the patient was re-administered with sunitinib by decreasing by 1 dose level after recovery. The minimum dose was 12.5 mg in all patients, and in the case of another intolerance, they would be permanently discontinued. All patients signed written informed consent before receiving treatment. This study was approved by the Ethics Committee of the Second Affiliated Hospital of Jiaxing University.

The extraction of total RNA from peripheral blood and tumour tissue of patients

Peripheral blood and tumour tissue was obtained from 50 patients before treatment. The extraction of total RNA from peripheral blood was as follows. After the patient was fasted for 12 h, 5 ml of peripheral blood was collected at the elbow, which was placed in a heparin anticoagulant
tube. After dilution with the same dose of PBS, mixing by pipetting at room temperature, a 1/2 diluted volume of lymphocyte separation solution (Histopaque-1077, Sigma, USA) was added to the centrifuge tube, added slowly along the wall of the tube, followed by centrifugation at 3000 rpm for 30 min to obtain peripheral blood mononuclear cells (PBMCs). The EZNA Blood RNA Mini Kit (Omega, US) was used to extract RNA from PBMCs. Total RNA was extracted and stored at −80°C, and cDNA was synthesized within 1 week and stored at −20°C. The extraction of RNA from tumour tissue was as follows. Briefly, a small amount of liquid nitrogen was added to the mortar, and we waited until the liquid nitrogen volatilized to completely pre-cool the mortar. An appropriate amount of liquid nitrogen was added, and tumour tissue was subsequently added to grind it, followed by the addition of 1 ml of TRIzol after powdering. After the tissue was completely dissolved, the homogenate was transferred to an EP tube. Afterwards, an Invitrogen TRIzol kit (Invitrogen, US) was used to extract RNA, which was stored at −80°C, and cDNA was synthesized within 1 week and stored at −20°C.

**Real-time quantitative PCR (RT-qPCR)**

Total RNA was reverse-transcribed using the PrimeScript™ RT reagent kit with gDNA Eraser kit (Takara, China). In the reaction system, 1 μg of RNA was contained in per 20 μl of the system. The reverse transcription was performed as follows: 7 μl of 60 ng/μl RNA, 2 μl of 5×gDNA Eraser buffer, and 1 μl of gDNA Erase were mixed and reacted for 1 min at 45°C, followed by the addition of 4 μl of 5×PrimeScript Enzyme Buffer, 1 μl of PrimeScript Enzyme, 1 μl of PrimeScript RT Mix, and 4 μl of nuclease-free H2O, which were mixed and incubated at 37°C for 15 min to obtain cDNAs. The synthesized cDNA was amplified using SYBR Premix Ex Taq II reagent (Takara, China) in a 10-μl reaction system. The reagents and procedures of qPCR were as follows: 5 μl of 2×SYBR®Premix Ex TaqTM and 0.2 μl Primer Forward (10 pmol/μl), 0.2 μl Primer Reverse (10 pmol/μl), 0.2 μl ROX Dye II, and 2.4 μl Nuclease-free H2O were mixed and amplified using ABI step one. The reaction conditions were as follows: 95°C for 2 min, 40 cycles of 15 s at 95°C and 30 s at 58°C; the fluorescence was collected at 58°C. The dissolution temperature was gradually increased from 58°C to 95°C, and fluorescence was collected by every 0.5°C increase. The IncRNA HOTAIR forward primer: 5’-GGCTGAACCTCCCTCCTGCTATT-3’, the reverse primer 5’-ACAC-AAAGTGATACACCTACCCA-3’ (329 bp in length). The internal reference β-actin forward primer 5’-AAGAGGGCATCTCCTACGG-3’, the reverse primer 5’-TACATGCCTGCGGTGTGG-3’ (216 bp in length).

**Statistical analysis**

SPSS19.0 software was used for statistical analysis. The measurement data were compared by t-test, analysis of variance and Mann-Whitney U test. The survival analysis was conducted by Kaplan-Meier method, followed by log-rank test for the comparison between groups. Cox regression analysis was used for univariate and multivariate analyses. \( P < 0.05 \) was considered as statistical significance.

**Results**

**Basic information of the patients**

A total of 60 patients were enrolled in this study, who were admitted and diagnosed with advanced-stage HCC at the Second Affiliated Hospital of Jiaxing University from January 2015 to December 2016. Among them, 35 were male and 25 were female, 38 were in stage III, and 22 were in stage IV. The median OS was 10.4 months (range: 6.5–18.7 months), and the median PFS was 6.8 (range: 3.8–11.6). The basic information of patients is shown in Table I.

| Factors                        | Number of cases | Percentage (%) |
|--------------------------------|-----------------|----------------|
| Age [years]:                   |                 |                |
| Median (range)                 | 64 (42–78)      | 58             |
| Gender:                        |                 |                |
| Male                           | 35              | 52             |
| Female                         | 25              | 42             |
| Alcohol drinking:              |                 |                |
| Yes                            | 31              | 52             |
| No                             | 29              | 48             |
| Stage:                         |                 |                |
| III                            | 38              | 63             |
| IV                             | 22              | 37             |
| Hepatocirrhosis:               |                 |                |
| Yes                            | 20              | 33             |
| No                             | 40              | 67             |
| Metastasis sites:              |                 |                |
| Lymph node                     | 25              | 41             |
| Lung                           | 15              | 25             |
| Bone                           | 10              | 17             |
| Others                         | 10              | 17             |

**The expression level of IncRNA HOTAIR in tumour tissue and peripheral blood of patients**

The average expression level of IncRNA HOTAIR in tumour tissues of HCC patients was 5.07 (range: 3.2–8.6). The average expression level of IncRNA HOTAIR in peripheral blood of patients was 0.03 (range: 0.01–0.05).
The correlation of the expression level of lncRNA HOTAIR with clinicopathological characteristics

The median of lncRNA HOTAIR expression in tumour tissues was 5.1, and the median of lncRNA HOTAIR expression in peripheral blood was 2.7. The medians were used as cut-offs, and patients were divided into a high-expression group (High) and a low-expression group (Low). The Mann-Whitney U test revealed that the expression level of lncRNA HOTAIR was not correlated with clinicopathological characteristics, including age ($p = 0.73, 0.93$), gender ($p = 0.38, 0.71$), drinking history ($p = 0.31, 0.31$), physical status ($p = 0.81, 0.78$), tumour stage ($p = 0.10, 0.23$), and cirrhosis history ($p = 0.69, 0.46$) (shown in Table II).

The correlation of OS and PFS with the expression level of lncRNA HOTAIR in tumour tissue and peripheral blood

The median OS of patients with low and high lncRNA HOTAIR expression in tumour tissue was 13.4 vs. 9.5 (log-rank 17.9, $p < 0.001$, Figure 3 A). The median OS of patients with low and high expression of lncRNA HOTAIR in peripheral blood was 12.8 vs. 9.1 (log-rank 16.3, $p < 0.001$, Figure 3 B). The median PFS of patients with low and high lncRNA HOTAIR expression in tumour tissues was 8.4 vs. 6.2 (log-rank 19.7, $p < 0.001$, Figure 3 C). The median PFS in patients with low and high lncRNA HOTAIR expression in peripheral blood was 8.9 vs. 6.4 (log-rank 18.3, $p < 0.001$, Figure 3 D). The median OS of patients with low expression of lncRNA in both tumours and peripheral blood and the rest of the patients was 14.3 vs. 8.8 (log-rank 21.8, $p < 0.001$, Figure 3 E). The median PFS of patients with low expression of lncRNA in both tumours and peripheral blood and the rest patients was 10.6 vs. 6.0 (log-rank 20.4, $p < 0.001$, Figure 3 F). The results were shown in Figure 3.

Correlation between OS and clinicopathological characteristics

The clinical stage and physical status of HCC patients were correlated with their OS (log-rank: 6.571, 5.351, $p = 0.013, 0.018$). COX regression analysis demonstrated that patients with low ex-
The expression of long non-coding RNA HOTAIR in advanced hepatocellular carcinoma and its prognostic correlation with sunitinib therapy

Arch Med Sci 1, December / 2021 75

expression of lncRNA HOTAIR in tumour or peripheral blood had longer OS (HR = 4.035, 4.135, p = 0.04, and 0.031). Patients with low expression of lncRNA HOTAIR in both tumour tissue and peripheral blood had further prolonged OS (HR = 9.873, p = 0.001). The results are shown in Table III.

Correlation between PFS and clinicopathological characteristics

The clinical stage and physical status of patients were correlated with their PFS (log-rank: 7.685, 6.354, p = 0.031, 0.038). COX regression analysis revealed that patients with low expression of lncRNA HOTAIR in tissues or peripheral blood had longer PFS (HR = 3.852, 3.168, p = 0.025, 0.026). Patients with low expression of lncRNA HOTAIR in both tumour tissue and peripheral blood had prolonged PFS (HR = 9.341, p = 0.001). The results are shown in Table IV.

Incidence of adverse reactions during sunitinib treatment

Digestive tract adverse reactions include the following: nausea, vomiting, diarrhoea, indigestion, constipation, etc. A total of 12 patients developed such adverse reactions, all of which were grade I, with an incidence of 20%. Two patients had abnormal liver function and recovered after drug reduction. One patient developed a rash and resumed after withdrawal, and no obvious adverse reactions were found in other patients. The incidence of gastrointestinal adverse reactions of sunitinib is the highest, but the degree is low, and patients can tolerate it.

Discussion

Primary liver cancer is a common malignancy and is particularly prevalent in Southeast Asian countries. HCC is one type of primary liver cancer with relatively high prevalence. In particular, a considerable proportion of patients are already in advanced stages when they are diagnosed. For those patients, treatment is relatively tough, and the prognosis is relatively poor. At present, great attention has been paid to multi-kinase inhibitor targeted drugs as therapeutic approaches to HCC. Currently, targeted drugs for HCC include somatostatin, sunitinib, etc. [8].

Sunitinib is a multi-kinase small molecule compound that inhibits tyrosine kinase targets such as VEGFR (VEGFR-1-3) and PDGFR. In a Phase II, multicentre, European/Asian clinical trial in 2006, the median OS was 44 weeks and the TPP was 21 weeks, in patients undergoing sunitinib monotherapy. According to Response Evaluation Criteria in Solid Tumours (RECIST), over 30% of tumours underwent necrosis after 1–1.5 months

| Clinical and pathological factors | lncRNA HOTAIR in tumour | lncRNA HOTAIR in peripheral blood |
|----------------------------------|-------------------------|----------------------------------|
|                                  | Low (n = 30)            | High (n = 30)                    | Low (n = 30)            | High (n = 30) |
| Age [years]:                     |                         |                                  |                      |
| ≤ 60                             | 13 (43)                 | 15 (50)                          | 14 (47)              | 14 (47)     |
| > 60                             | 17 (57)                 | 15 (50)                          | 16 (53)              | 16 (53)     |
| Gender:                          |                         |                                  |                      |
| Male                             | 16 (53)                 | 19 (63)                          | 17 (57)              | 18 (60)     |
| Female                           | 14 (47)                 | 11 (37)                          | 13 (43)              | 12 (40)     |
| Alcohol drinking:                |                         |                                  |                      |
| Yes                              | 17 (57)                 | 14 (47)                          | 17 (57)              | 14 (47)     |
| No                               | 13 (43)                 | 16 (53)                          | 13 (43)              | 16 (53)     |
| Performance status:              |                         |                                  |                      |
| 0                                | 14 (47)                 | 15 (50)                          | 15 (50)              | 14 (47)     |
| 1                                | 16 (53)                 | 15 (50)                          | 15 (50)              | 16 (53)     |
| Hepatocirrhosis:                 |                         |                                  |                      |
| Yes                              | 9 (30)                  | 11 (37)                          | 8 (27)               | 12 (40)     |
| No                               | 21 (70)                 | 19 (63)                          | 22 (73)              | 18 (60)     |
| Tumour stage:                    |                         |                                  |                      |
| III                              | 21 (70)                 | 17 (57)                          | 20 (67)              | 18 (60)     |
| IV                               | 9 (30)                  | 13 (43)                          | 10 (33)              | 12 (40)     |

No significant differences were observed between the levels of gene expression as dichotomous variable (low vs. high) across clinical and pathological factors using the Mann-Whitney U test (p > 0.05).
of treatment, indicating that sunitinib exerted an anti-hepatocarcinogenic effect [9]. The second phase II clinical trial showed [10] that of the 45 patients with advanced HCC treated with 37.5 mg/day sunitinib, 15 patients were still alive and had no significant progress after 12 weeks. The median TPP was 3.2 months, and the median OS was 9.3 months, which was consistent with our findings (median OS: 10.4 months, ranging from 6.5 to 18.7 months, median PFS: 6.8, ranging from 3.8 to 11.6 months), suggesting that sunitinib has little difference in overall efficacy in HCC therapy, and consistency with previous studies. However, in previous studies, we found that the therapeutic efficacy of sunitinib in HCC patients was quite different. In addition, there is no study concerning the efficacy prediction and evaluation. We speculate that it might be related to HCC progression, primary resistance of patients, acquired drug resistance, and adaptive drug resistance.
The expression of long non-coding RNA HOTAIR in advanced hepatocellular carcinoma and its prognostic correlation with sunitinib therapy

In the study of tumours, there have been extensive studies concerning non-coding RNA as a marker of tumour prognosis, especially lncRNA. lncRNA HOTAIR is relatively mature in the study of tumours. The present reports demonstrate that the expression of lncRNA HOTAIR is high in a variety of tumours. Gupta et al. have reported that lncRNA HOTAIR is an important prognostic indicator in primary breast cancer, and lncRNA HOTAIR can regulate tumour metastasis [11]. Kogo et al. [12] found that lncRNA HOTAIR plays a critical role in stage IV colorectal cancer, confirming that the expression of lncRNA HOTAIR in colorectal cancer is higher than that in adjacent tissues. Yang et al. [13] found that the increased expression of lncRNA HOTAIR is associated with tumour recurrence.

### Table III. The correlation between OS and clinicopathological characteristics

| Clinical and pathological factors | Number of patients | Median OS [month] | Univariate analysis | Multivariate analysis |
|-----------------------------------|--------------------|-------------------|--------------------|----------------------|
|                                   |                    |                   | Log-rank | P-value | HR (95% CI) | P-value |
| Stage:                            |                    |                   |         |         |             |         |
| III                               | 38                 | 13.7 (8.6–18.7)   | 6.571   | 0.013   | 2.134 (0.832–3.938) | 0.083   |
| IV                                | 22                 | 10.1 (6.5–15.2)   |         |         |             |         |
| Performance status:               |                    |                   |         |         |             |         |
| 0                                 | 29                 | 13.6 (8.9–18.7)   | 5.351   | 0.018   | 2.865 (0.911–4.325) | 0.024   |
| 1                                 | 31                 | 10.2 (6.5–15.0)   |         |         |             |         |
| In peripheral blood:              |                    |                   |         |         |             |         |
| HOTAIR Low                        | 30                 | 12.8 (7.8–18.7)   | 6.857   | 0.016   | 4.035 (1.731–5.854) | 0.040   |
| HOTAIR High                       | 30                 | 9.1 (6.5–12.6)    |         |         |             |         |
| In tumour tissue:                 |                    |                   |         |         |             |         |
| HOTAIR Low                        | 30                 | 13.4 (8.9–18.7)   | 6.147   | 0.012   | 4.135 (1.832–6.154) | 0.031   |
| HOTAIR High                       | 30                 | 9.5 (6.5–13.0)    |         |         |             |         |
| In peripheral blood and tumour tissue: |        |                   |         |         |             |         |
| Both low                          | 24                 | 14.3 (10.0–18.7)  | 10.87   | 0.001   | 9.873 (2.867–21.368) | 0.001   |

### Table IV. The correlation between PFS and clinicopathological characteristics

| Clinical and pathological factors | Number of patients | Median OS [month] | Univariate analysis | Multivariate analysis |
|-----------------------------------|--------------------|-------------------|--------------------|----------------------|
|                                   |                    |                   | Log-rank | P-value | HR (95% CI) | P-value |
| Stage:                            |                    |                   |         |         |             |         |
| III                               | 38                 | 9.0 (6.3–11.6)    | 7.685   | 0.031   | 3.120 (1.132–11.240) | 0.024   |
| IV                                | 22                 | 6.5 (3.8–9.5)     |         |         |             |         |
| Performance status:               |                    |                   |         |         |             |         |
| 0                                 | 29                 | 9.2 (6.5–11.6)    | 6.354   | 0.038   | 3.138 (1.854–9.543) | 0.031   |
| 1                                 | 31                 | 6.1 (3.8–9.2)     |         |         |             |         |
| In peripheral blood:              |                    |                   |         |         |             |         |
| HOTAIR Low                        | 30                 | 8.9 (6.1–11.6)    | 5.864   | 0.032   | 3.852 (1.358–13.210) | 0.025   |
| HOTAIR High                       | 30                 | 6.4 (3.8–9.4)     |         |         |             |         |
| In tumour tissue:                 |                    |                   |         |         |             |         |
| HOTAIR Low                        | 30                 | 8.4 (5.4–11.6)    | 8.358   | 0.013   | 3.168 (1.281–12.854) | 0.026   |
| HOTAIR High                       | 30                 | 6.2 (3.8–8.8)     |         |         |             |         |
| In peripheral blood and tumour tissue: |        |                   |         |         |             |         |
| Both low                          | 24                 | 10.6 (9.2–11.6)   | 11.563  | 0.001   | 9.341 (3.152–21.574) | 0.001   |
following liver transplantation in HCC patients, which can be used as an independent prognostic factor. In the study of drug resistance, the sensitivity of tumour cells to cisplatin and doxorubicin is correlated with the expression level of IncRNA HOTAIR [14, 15], indicating that IncRNA HOTAIR not only serve as a biomarker for tumour prognosis but also as a potential therapeutic target.

From the results of this study, the expression of IncRNA HOTAIR is high in patients with advanced HCC, and this high expression of IncRNA HOTAIR is not correlated with clinicopathological characteristics, and the expression level of IncRNA HOTAIR in tumour tissue and peripheral blood is correlated (r = 0.638, p < 0.001), which are consistent with previous studies, indicating that IncRNA HOTAIR also plays an important role in HCC. In the analysis of survival, patients with low expression of IncRNA HOTAIR in tumour tissue and peripheral blood are more likely to benefit from sunitinib therapy, obtaining longer OS and PFS. In addition, COX regression analysis showed that IncRNA HOTAIR was an independent prognostic factor for sunitinib in treating advanced HCC.

Collectively, we demonstrate that IncRNA HOTAIR is highly expressed in tissues and peripheral blood of patients with advanced HCC, and IncRNA HOTAIR can be used as an independent prognostic factor for sunitinib in treating advanced HCC. However, the exact conclusions require a larger sample size to be verified, and how IncRNA HOTAIR affects the efficacy of sunitinib remains to be further studied. In summary, this study provides a new idea for the individualized therapy of sunitinib in clinical practice.

In conclusion, IncRNA HOTAIR is highly expressed in tissues and peripheral blood of patients with advanced HCC, and IncRNA HOTAIR can be used as an independent prognostic factor for sunitinib in treating advanced HCC.

Acknowledgments

Thanks to The Second Affiliated Hospital of Jiaxing University for providing experimental sites and theoretical support, thanks to the laboratory workers in the central laboratory.

Conflict of interest

The authors declare no conflict of interest.

Reference

1. Sakurai Y, Kubota N, Takamoto I, et al. Role of insulin receptor substrates in the progression of hepatocellular carcinoma. Sci Rep 2017; 7: 5387.

2. Hammond JS, Franko J, Holloway SE, et al. Gemcitabine transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. Hepatogastroenterology 2014; 61: 1339-43.

3. Ippolito D, Fior D, Bonaffini PA, et al. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients. Eur J Radiol 2014; 83: 1665-71.

4. Simonneau E, Vauthey JN. Progression of colorectal cancer liver metastasis after chemotherapy: a new test of time? Ann Surg Oncol 2018; 25: 1469-70.

5. Ruiz-Morales JM, Swierkowski M, Wells JC, et al. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur J Cancer 2016; 65: 102-8.

6. Oudard S, Geoffrois L, Guillot A, et al. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma—Results of the REchallenge with SUItinib in METastatic RCC (RESUME) Study. Eur J Cancer 2016; 62: 28-35.

7. Botti G, Marra L, Malzone MG, et al. Long non-coding RNA HOTAIR as prognostic circulating marker and potential therapeutic target in patients with tumor diseases. Current Drug Targets 2016; 18: 27-34.

8. Poelstra K, Prakash J, Beljaars L. Drug targeting to the diseased liver. J Control Release 2012; 161: 188-97.

9. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.

10. Koebel D, Montemurro M, Samaras P, et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06). Oncologist 2010; 15: 285-92.

11. Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464: 1071-6.

12. Kogo R, Shimamura T, Mimori K, et al. Long noncoding RNA hotair regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 2011; 71: 6320-6.

13. Yang Z, Zhou L, Wu LM, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol 2011; 18: 1243-50.

14. Liu MY, Li XQ, Gao TH, et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: results of the REchallenge with SUItinib in METastatic RCC (RESUME) Study. Eur J Cancer 2016; 65: 102-8.

15. Banas T, Pitynski K, Okon K, et al. Immunexpression of DNA fragmentation factor 40, DNA fragmentation factor 45, and B-cell lymphoma 2 protein in normal human endometrium and uterine myometrium depends on menstrual cycle phase and menopausal status. Arch Med Sci 2017; 14: 1254-62.